Biotech company Enzene Biosciences (Enzene), a subsidiary of Alkem Laboratories, has raised $50 million in funding to strengthen its manufacturing capabilities and expand in India and the US.
Dr Prem Pavoor, Senior Partner, Head of India & Healthcare Investments, Eight Roads Ventures, stated: “We are thrilled to be partnering with Alkem Laboratories and Enzene to build a global biosimilars and biologics powerhouse out of India.”
Based in Pune, Enzene boasts fully-integrated biotech process development and manufacturing capabilities across multiple modalities and platforms. The company has developed its own pipeline of biosimilars which have been licensed to pharmaceutical companies across global markets.
Additionally, it provides end-to-end contract, development and manufacturing services to biotechnology companies. Its biologics services include clone development and GMP (good manufacturing practice) supported by bioreactor capacities ranging from 20 litres to 2,000 litres. It specializes in producing biosimilars, novel biologics, synthetic peptides, and phytopharmaceuticals.
Enzene’s CEO, Dr Himanshu Gadgil commented: “We are delighted to have Eight Roads Ventures and F-Prime Capital as our investors. Their expertise and global network will help us to accelerate our mission.”
Through this funding, Enzene hopes to continue its mission towards delivering innovative and cost effective bio-manufacturing for biosimilars and novel biologics globally.
Enzene Biosciences plans global foray
According the company website – Enzene has invested in technologies of the future to allow fully integrated development, beginning with cell line engineering to drug product development. We have the state-of-the-art analytical lab for comprehensive characterization of mAbs, high throughput screening technologies in our upstream as well as downstream process development. We have a proprietary cloning platform and internal regulatory science, which caters to most of the filing requirements.
Enzene has end to end development platform from its own propriety CHO duos cell lines, to high throughput upstream and downstream platforms, comprehensive drug product development capabilities backed by state of the art advanced analytical technologies supports speedy development of pre-clinical and clinical drug candidates. We are pioneers in Continuous Bioprocess manufacturing and are capable of offering varied scientific support to our clients.
Enzene CDMO provides access to an affordable, disruptive manufacturing platform for clinical candidates. Along with providing fully continuous end-end solutions, we also offer flexibility in terms of adapting to a fed-batch process. Enzene has built technical expertise in terms of talent and infrastructure, which will allow us to deliver to the ever demanding needs of biosimilar market.
The funding was led by Alkem Laboratories, Eight Roads Ventures, and F-Prime Capital.
